Previous Article | Next Article ![]()
Infect Immun, July 1998, p. 3190-3197, Vol. 66, No. 7
Eijkman-Winkler Institute for Microbiology,
Received 9 March 1998/Accepted 22 April 1998
Induction of cytotoxic T lymphocytes (CTLs) by vaccination has been
shown to protect against bacterial, viral, and tumoral challenge. The
aim of this study was to identify CTL epitopes on the 38-kDa
lipoglycoprotein from Mycobacterium tuberculosis. The
identification of these CTL epitopes was based on synthesizing peptides
designed from the 38-kDa lipoglycoprotein, with known major
histocompatibility complex class I (MHC-I) binding motifs (H-2Db), and studying their ability to up-regulate and
stabilize MHC-I molecules on the mouse lymphoma cell line RMA-S. To
improve the capacity of the identified peptides to induce CTL responses
in mice, palmitic acid with a cysteine-serine-serine spacer amino acid
sequence was attached to the amino terminus of the peptide. Two of five
peptides with H-2Db binding motifs and their corresponding
lipopeptides up-regulated and stabilized the H-2Db
molecules on RMA-S cells. Both lipopeptides, in combination with incomplete Freund's adjuvant, induced CTL responses in C57BL/6 (H-2b) mice. Moreover, the lipopeptide induced stronger CTL
responses than the peptide. The capacity of the various lipopeptides to induce CTL displayed a good relationship with the ability of the (lipo)peptide to up-regulate and to stabilize H-2Db
molecules. The capacity of the peptides and lipopeptides to up-regulate and stabilize MHC-I expression can therefore be used to predict their
potential to function as a CTL epitope. The newly identified CTL
epitopes and their lipid derivatives provide us with important information for future M. tuberculosis vaccine design.
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Identification of New Cytotoxic T-Cell Epitopes on the
38-Kilodalton Lipoglycoprotein of Mycobacterium
tuberculosis by Using Lipopeptides
German National Research
Center for Biotechnology, 38124 Braunschweig,
Germany4; and
Veterinary Laboratories
Agency, Bacteriology, TB Research Group, New Haw, Addlestone,
Surrey KT13 3NB, United Kingdom5
*
Corresponding author. Mailing address: Eijkman-Winkler
Institute for Microbiology, Infectious Diseases, and Inflammation, Section Vaccines, AZU, Rm. G04.614, Utrecht University, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. Phone: 31-30-2506525. Fax: 31-30-2541770. E-mail: D.Fonseca{at}lab.azu.nl.
Infect Immun, July 1998, p. 3190-3197, Vol. 66, No. 7
0019-9567/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|